$BRNS
Barinthus Biotherapeutics plc American Depositary Shares
XNAS
Why is BRNS down today? It is at $0.570 (-0.02%). See the catalyst behind the move, real-time alerts the moment BRNS spikes, and full due diligence on BRNS — key stats, earnings, dilution and insider activity. Free.
Get free $BRNS alerts the moment volume spikes
Be first to know when $BRNS makes an unusual move. Create a free account to track $BRNS, build a watchlist, and get instant unusual-volume alerts — plus 5 free premium days, no card needed.
No card · 5 premium days · join 800+ traders
Key Stats
- Price
- $0.570
- Change today
- -0.02%
- Previous close
- $0.570
- 52-week range
- $0.512 – $1.83
- Market cap
- $23M
- Institutional own.
- 22.76%
- Total held
- 31.8%
- Tradeable float
- 27.9M 68% of shares · after 9% insiders + 23% institutions
- Short interest
- 29K ▼ -34% vs prior · as of 2026-07-15
- Short % of float
- 0.1%
- Days to cover
- 1.0d
- Avg daily volume
- 78K
- Exchange
- XNAS
- 5mthin
- 24x
- 15mthin
- 24x
- 1hthin
- 24x
- 1D
- 6.5x
Get free BRNS + market alerts in your inbox
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Why is $BRNS moving today?
Here is the latest on BRNS from our scanner (live price and day move above). Fresh from the SEC: Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments. A material company disclosure like this is often the real catalyst behind a move of this size.
Likely catalystBarinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate DevelopmentsReported Completed enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in patients with celiac disease; topline data from multiple ascending dose ("MAD") expected in the fourth quarter of 2026.Reported During the third quarter of 2026, Barinthus Bio completed enrollment in all cohorts in the MAD portion of the Phase 1 AVALON clinical trial.Reported Data from the MAD portion of the Phase 1 AVALON clinical trial, which includes a gluten challenge following three doses of test medication, is expected in the fourth quarter of 2026., from the latest SEC filing. Read it →$BRNS Sentiment
NeutralBlend of news sentiment, today’s move, and community votes. Not investment advice.
$BRNS Activity
News, unusual-volume alerts, AI-trader trades and community chatter — the whole story, newest first.
BRNS stock FAQ
Why is $BRNS moving today?
Here is the latest on BRNS from our scanner (live price and day move above). Fresh from the SEC: Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments. A material company disclosure like this is often the real catalyst behind a move of this size.
What is the BRNS stock price today?
BRNS last traded at $0.570, down 0.02% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Where can I see live BRNS alerts?
The BRNS Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged BRNS 0 times in the last 30 days.
What exchange is BRNS on?
BRNS (Barinthus Biotherapeutics plc American Depositary Shares) trades on XNAS, with a market cap of about $23M.
Is BRNS good for day trading?
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge BRNS for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.